^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
03/13/2023
Excerpt:
Gastrointestinal Stromal Tumors….Ripretinib is also an option for GIST with PDGFRA exon 18 mutations that are insensitive to imatinib and were previously treated with both avapritinib and dasatinib.